Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its antineoplastic activity

Ganesh Chandra Jagetia, Tiyyagura Koti Reddy, Krishna Jayacharya Malagi, Bijoor Shivananda Nayak, Menda Balachandra Rao Naidu, Penumurthy Balaji Ravikiran, Shobha Ullas Kamath, Prukash Chandra Shetty, Dondapati Subba Reddy

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Doxorubicin (DOX), an anthracycline drug widely used for the treatment of various cancers, causes a cumulative dose-dependent cardiotoxicity that is characterized by an irreversible dilated cardiomyopathy and congestive heart failure. Antarth (ANT) a polyherbal preparation was evaluated for its cardioprotective properties against doxorubicin-induced cardiotoxicity in mice. Mice were treated with 25 mg/kg ANT orally once daily for 5 consecutive days before a single intraperitoneal injection of 15 mg/kg doxoubicin. The animals were killed 30 h after DOX treatment. DOX induced a significant elevation in the serum levels of glutamic pyruvic transaminase (GPT), glutamic oxaloacetic transaminase (GOT), creatine kinase (CK-MB) and lactate dehydrogenase (LDH), indicating its acute cardiotoxicity. The treatment of mice with ANT before DOX administration significantly reduced the serum levels of GPT, GOT, CK-MB and LDH indicating that ANT protected against the DOX-induced cardiotoxicity. Pretreatment of mice with 25 mg/kg ANT inhibited the DOX-induced decline in the antioxidant status. Intraperitoneal injection of 1.25 mg/kg DOX once daily for 9 consecutive days significantly improved the survival of mice bearing Ehrlich ascites carcinoma (EAC). Treatment of EAC with 25 mg/kg ANT alone did not affect the anticancer activity of DOX since ANT did not alter the tumor cell growth, the median survival time and average survival time of tumor bearing mice. The present study demonstrates that ANT protects mice against DOX-induced cardiotoxicity, without compromising the antineoplastic activity of DOX.

Original languageEnglish
Pages (from-to)772-778
Number of pages7
JournalPhytotherapy Research
Volume19
Issue number9
DOIs
Publication statusPublished - 09-2005

Fingerprint

Antineoplastic Agents
Doxorubicin
Aspartate Aminotransferases
Intraperitoneal Injections
Alanine Transaminase
L-Lactate Dehydrogenase
Ascites
antarth
Carcinoma
MB Form Creatine Kinase
Neoplasms
Anthracyclines
Dilated Cardiomyopathy
Therapeutics
Serum
Heart Failure
Antioxidants
Cardiotoxicity

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Jagetia, G. C., Reddy, T. K., Malagi, K. J., Nayak, B. S., Naidu, M. B. R., Ravikiran, P. B., ... Reddy, D. S. (2005). Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its antineoplastic activity. Phytotherapy Research, 19(9), 772-778. https://doi.org/10.1002/ptr.1713
Jagetia, Ganesh Chandra ; Reddy, Tiyyagura Koti ; Malagi, Krishna Jayacharya ; Nayak, Bijoor Shivananda ; Naidu, Menda Balachandra Rao ; Ravikiran, Penumurthy Balaji ; Kamath, Shobha Ullas ; Shetty, Prukash Chandra ; Reddy, Dondapati Subba. / Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its antineoplastic activity. In: Phytotherapy Research. 2005 ; Vol. 19, No. 9. pp. 772-778.
@article{7fa84f6cef184286882a626174e06a91,
title = "Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its antineoplastic activity",
abstract = "Doxorubicin (DOX), an anthracycline drug widely used for the treatment of various cancers, causes a cumulative dose-dependent cardiotoxicity that is characterized by an irreversible dilated cardiomyopathy and congestive heart failure. Antarth (ANT) a polyherbal preparation was evaluated for its cardioprotective properties against doxorubicin-induced cardiotoxicity in mice. Mice were treated with 25 mg/kg ANT orally once daily for 5 consecutive days before a single intraperitoneal injection of 15 mg/kg doxoubicin. The animals were killed 30 h after DOX treatment. DOX induced a significant elevation in the serum levels of glutamic pyruvic transaminase (GPT), glutamic oxaloacetic transaminase (GOT), creatine kinase (CK-MB) and lactate dehydrogenase (LDH), indicating its acute cardiotoxicity. The treatment of mice with ANT before DOX administration significantly reduced the serum levels of GPT, GOT, CK-MB and LDH indicating that ANT protected against the DOX-induced cardiotoxicity. Pretreatment of mice with 25 mg/kg ANT inhibited the DOX-induced decline in the antioxidant status. Intraperitoneal injection of 1.25 mg/kg DOX once daily for 9 consecutive days significantly improved the survival of mice bearing Ehrlich ascites carcinoma (EAC). Treatment of EAC with 25 mg/kg ANT alone did not affect the anticancer activity of DOX since ANT did not alter the tumor cell growth, the median survival time and average survival time of tumor bearing mice. The present study demonstrates that ANT protects mice against DOX-induced cardiotoxicity, without compromising the antineoplastic activity of DOX.",
author = "Jagetia, {Ganesh Chandra} and Reddy, {Tiyyagura Koti} and Malagi, {Krishna Jayacharya} and Nayak, {Bijoor Shivananda} and Naidu, {Menda Balachandra Rao} and Ravikiran, {Penumurthy Balaji} and Kamath, {Shobha Ullas} and Shetty, {Prukash Chandra} and Reddy, {Dondapati Subba}",
year = "2005",
month = "9",
doi = "10.1002/ptr.1713",
language = "English",
volume = "19",
pages = "772--778",
journal = "Phytotherapy Research",
issn = "0951-418X",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its antineoplastic activity. / Jagetia, Ganesh Chandra; Reddy, Tiyyagura Koti; Malagi, Krishna Jayacharya; Nayak, Bijoor Shivananda; Naidu, Menda Balachandra Rao; Ravikiran, Penumurthy Balaji; Kamath, Shobha Ullas; Shetty, Prukash Chandra; Reddy, Dondapati Subba.

In: Phytotherapy Research, Vol. 19, No. 9, 09.2005, p. 772-778.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its antineoplastic activity

AU - Jagetia, Ganesh Chandra

AU - Reddy, Tiyyagura Koti

AU - Malagi, Krishna Jayacharya

AU - Nayak, Bijoor Shivananda

AU - Naidu, Menda Balachandra Rao

AU - Ravikiran, Penumurthy Balaji

AU - Kamath, Shobha Ullas

AU - Shetty, Prukash Chandra

AU - Reddy, Dondapati Subba

PY - 2005/9

Y1 - 2005/9

N2 - Doxorubicin (DOX), an anthracycline drug widely used for the treatment of various cancers, causes a cumulative dose-dependent cardiotoxicity that is characterized by an irreversible dilated cardiomyopathy and congestive heart failure. Antarth (ANT) a polyherbal preparation was evaluated for its cardioprotective properties against doxorubicin-induced cardiotoxicity in mice. Mice were treated with 25 mg/kg ANT orally once daily for 5 consecutive days before a single intraperitoneal injection of 15 mg/kg doxoubicin. The animals were killed 30 h after DOX treatment. DOX induced a significant elevation in the serum levels of glutamic pyruvic transaminase (GPT), glutamic oxaloacetic transaminase (GOT), creatine kinase (CK-MB) and lactate dehydrogenase (LDH), indicating its acute cardiotoxicity. The treatment of mice with ANT before DOX administration significantly reduced the serum levels of GPT, GOT, CK-MB and LDH indicating that ANT protected against the DOX-induced cardiotoxicity. Pretreatment of mice with 25 mg/kg ANT inhibited the DOX-induced decline in the antioxidant status. Intraperitoneal injection of 1.25 mg/kg DOX once daily for 9 consecutive days significantly improved the survival of mice bearing Ehrlich ascites carcinoma (EAC). Treatment of EAC with 25 mg/kg ANT alone did not affect the anticancer activity of DOX since ANT did not alter the tumor cell growth, the median survival time and average survival time of tumor bearing mice. The present study demonstrates that ANT protects mice against DOX-induced cardiotoxicity, without compromising the antineoplastic activity of DOX.

AB - Doxorubicin (DOX), an anthracycline drug widely used for the treatment of various cancers, causes a cumulative dose-dependent cardiotoxicity that is characterized by an irreversible dilated cardiomyopathy and congestive heart failure. Antarth (ANT) a polyherbal preparation was evaluated for its cardioprotective properties against doxorubicin-induced cardiotoxicity in mice. Mice were treated with 25 mg/kg ANT orally once daily for 5 consecutive days before a single intraperitoneal injection of 15 mg/kg doxoubicin. The animals were killed 30 h after DOX treatment. DOX induced a significant elevation in the serum levels of glutamic pyruvic transaminase (GPT), glutamic oxaloacetic transaminase (GOT), creatine kinase (CK-MB) and lactate dehydrogenase (LDH), indicating its acute cardiotoxicity. The treatment of mice with ANT before DOX administration significantly reduced the serum levels of GPT, GOT, CK-MB and LDH indicating that ANT protected against the DOX-induced cardiotoxicity. Pretreatment of mice with 25 mg/kg ANT inhibited the DOX-induced decline in the antioxidant status. Intraperitoneal injection of 1.25 mg/kg DOX once daily for 9 consecutive days significantly improved the survival of mice bearing Ehrlich ascites carcinoma (EAC). Treatment of EAC with 25 mg/kg ANT alone did not affect the anticancer activity of DOX since ANT did not alter the tumor cell growth, the median survival time and average survival time of tumor bearing mice. The present study demonstrates that ANT protects mice against DOX-induced cardiotoxicity, without compromising the antineoplastic activity of DOX.

UR - http://www.scopus.com/inward/record.url?scp=27644537614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644537614&partnerID=8YFLogxK

U2 - 10.1002/ptr.1713

DO - 10.1002/ptr.1713

M3 - Article

VL - 19

SP - 772

EP - 778

JO - Phytotherapy Research

JF - Phytotherapy Research

SN - 0951-418X

IS - 9

ER -